SV2008002868A - DIHYDROGEN SALT PHOSPHATE OF AN ANTAGONIST OF PROSTAGLANDINA D2 RECEIVER - Google Patents
DIHYDROGEN SALT PHOSPHATE OF AN ANTAGONIST OF PROSTAGLANDINA D2 RECEIVERInfo
- Publication number
- SV2008002868A SV2008002868A SV2008002868A SV2008002868A SV2008002868A SV 2008002868 A SV2008002868 A SV 2008002868A SV 2008002868 A SV2008002868 A SV 2008002868A SV 2008002868 A SV2008002868 A SV 2008002868A SV 2008002868 A SV2008002868 A SV 2008002868A
- Authority
- SV
- El Salvador
- Prior art keywords
- columbia
- administration
- successories
- cultural
- formula
- Prior art date
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000004624 Dermatitis Diseases 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010003645 Atopy Diseases 0.000 abstract 1
- -1 BUT NOT LIMITED TO Chemical compound 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 238000010009 beating Methods 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024711 extrinsic asthma Diseases 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000008585 mastocytosis Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA AL ÁCIDO FOSFÓRICO ÁCIDO 2-(3-{6-[2-(2,4-DICLORO-FENIL)-ETILAMINO]-2-METOXI-PIRIMIDIN-4-IL}-FENIL)-2-RNETIL-PROPIÓNICO DE FÓRMULA (III): (VER FORMULA); UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNA CANTIDAD FARMACÉUTICAMENTE EFICAZ DEL COMPUESTO DE FÓRMULA (III), Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE; Y UN MÉTODO DE TRATAR A UN PACIENTE QUE PADECE DE UN TRASTORNO MEDIADO POR PGD2 QUE INCLUYE, PERO NO SE LIMITA A, ENFERMEDAD ALÉRGICA (TAL COMO RINITIS ALÉRGICA, CONJUNTIVITIS ALÉRGICA, DERMATITIS ATÓPICA, ASMA BRONQUIAL Y ALERGIA ALIMENTARIA), MASTOCITOSIS SISTÉMICA, TRASTORNOS ACOMPAÑADOS POR LA ACTIVACIÓN SISTÉMICA DE LOS MASTOCITOS, CHOQUE ANAFILÁCTICO, BRONCOCONSTRICCIÓN, BRONQUITIS, URTICARIA, ECZEMA, ENFERMEDADES ACOMPAÑADAS POR PICOR (TALES COMO DERMATITIS ATÓPICA Y URTICARIA), ENFERMEDADES (TALES COMO CATARATAS, DESPRENDIMIENTO DE RETINA, INFLAMACIÓN, INFECCIÓN Y TRASTORNOS DEL SUEÑO) QUE SE GENERAN DE FORMA SECUNDARIA COMO RESULTADO DE LA CONDUCTA ACOMPAÑADA POR PICOR (TAL COMO RASCARSE Y GOLPEARSE), INFLAMACIÓN, ENFERMEDADES PULMONARES OBSTRUCTIVAS CRÓNICAS, LESIÓN DE REPERFUSIÓN ISQUÉMICA, ACCIDENTE CEREBROVASCULAR, ARTRITIS REUMATOIDE CRÓNICA, PLEURESÍA, COLITIS ULCEROSA Y SIMILARES, ADMINISTRANDO A DICHO PACIENTE UNA CANTIDAD FARMACÉUTICAMENTE EFICAZ DEL COMPUESTO DE FÓRMULA (III)THIS INVENTION IS DIRECTED TO THE ACID PHOSPHORIC ACID 2- (3- {6- [2- (2,4-DICLORO-PHENYL) -ETILAMINO] -2-METOXI-PYRIMIDIN-4-IL} -PHENILE) -2-RNETIL -PROPIONIC FORMULA (III): (SEE FORMULA); A PHARMACEUTICAL COMPOSITION THAT INCLUDES A PHARMACEUTICALLY EFFECTIVE AMOUNT OF THE FORMULA COMPOUND (III), AND A PHARMACEUTICALLY ACCEPTABLE VEHICLE; And a method of treating a patient suffering from a disorder mediated by PGD2 INCLUDING, BUT NOT LIMITED TO, allergic disease (such as Allergic Rhinitis, Conjunctivitis ALLERGY, ATOPIC DERMATITIS, ASTHMA AND FOOD ALLERGY), Mastocytosis, DISORDERS ACCOMPANIED BY THE SYSTEMIC ACTIVATION OF THE MASTOCYTS, ANAFILACTIC SHOCK, BRONCOCONSTRICTION, BRONCHITIS, URTICARIA, ECZEMA, DISEASES ACCOMPANIED BY PICOR (SUCH AS ATOPIC AND URTICARY DERMATITIS), DISEASES, INFLATEMENT, DISTRIBUTION, SUCCESSORIES, SUCCESSORIES, SUCCESSORIES, TREATMENTS, INFLATION ) THAT THEY ARE GENERATED SECONDARY AS A RESULT OF THE BEHAVIOR ACCOMPANIED BY PICOR (SUCH AS SCRAPPING AND BEATING), INFLAMMATION, CHRONIC OBSTRUCTIVE PULMONARY DISEASES, ISCHEMIC REPERFUSION INJURY, CEREBROVISCULTISTICAL ADMINISTRATION, COLUMBIA, CULTURAL ADMINISTRATION, COLUMBIA, CULTURAL ADMINISTRATION, COLUMBIA, CULTURAL ADMINISTRATION, COLUMBIA, ADMINISTRATION, COLUMBIA, ADMINISTRATION, COLUMBIA, ADULTS A PATIENT SUCH A PHARMACEUTICALLY EFI AMOUNT FORMULA COMPOSITE CAZ (III)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SV2008002868A SV2008002868A (en) | 2008-04-11 | 2008-04-11 | DIHYDROGEN SALT PHOSPHATE OF AN ANTAGONIST OF PROSTAGLANDINA D2 RECEIVER |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SV2008002868A SV2008002868A (en) | 2008-04-11 | 2008-04-11 | DIHYDROGEN SALT PHOSPHATE OF AN ANTAGONIST OF PROSTAGLANDINA D2 RECEIVER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2008002868A true SV2008002868A (en) | 2009-10-15 |
Family
ID=41591703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2008002868A SV2008002868A (en) | 2008-04-11 | 2008-04-11 | DIHYDROGEN SALT PHOSPHATE OF AN ANTAGONIST OF PROSTAGLANDINA D2 RECEIVER |
Country Status (1)
| Country | Link |
|---|---|
| SV (1) | SV2008002868A (en) |
-
2008
- 2008-04-11 SV SV2008002868A patent/SV2008002868A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200600457A (en) | DIHYDROGEN PHOSPHATE SALT AS ANTAGONIST OF PROSTAGLANDINA D2 RECEPTOR | |
| CR9003A (en) | 2.6 REPLACED-4-AMINO-PYRIMIDINE MONOSUSTITUTED AS ANTAGONIST OF THE PROSTAGLANDIN REPECTOR D2 | |
| EA201270561A1 (en) | CGRP RECEPTOR ANTAGONISTS | |
| TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| ECSP088813A (en) | AMINO-PYRIMIDINE COMPOUNDS 2,6-SUBSTITUTED-4-MONOSUSTITUTED AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEIVER | |
| DOP2006000016A (en) | 2-PHENYL-INDOLES AS ANTAGONISTS OF THE PROSTAGLANDIN RECEPTOR D2. | |
| BR112014002202A2 (en) | macrocycles as factor xia inhibitors | |
| EA200900472A1 (en) | PHOSPHODESTERASE INHIBITORS IV TYPE | |
| MX2012007711A (en) | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen. | |
| CL2009001759A1 (en) | Compound (4- (5-aminomethyl-2-fluorophenyl) piperidin-1-yl) (7-fluoro-1 (2-methoxyethyl) -4-trifluoromethoxy-1h-indol-3-yl) methanone; crystalline form a of the benzoate salt; intermediate compounds; pharmaceutical composition; and use in the treatment of inflammatory diseases, such as COPD, allergy, atopic dermatitis, among others. | |
| SV2008002868A (en) | DIHYDROGEN SALT PHOSPHATE OF AN ANTAGONIST OF PROSTAGLANDINA D2 RECEIVER | |
| DOP2010000238A (en) | DUE PHARMACOPHORIS-MUSCARINIC ANTAGONISTS OF PDE4 | |
| AR080527A1 (en) | A PYRIMIDINE REPLACED AS AN ANTAGONIST OF THE D2 POSTAGLANDINE RECEIVER | |
| WO2012029032A3 (en) | Heterocyclic compounds as dgat1 inhibitors | |
| MX2010008685A (en) | Dual pharmacophores-pde4-muscarinic antagonistics. | |
| UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| DOP2009000009A (en) | 2-PHENYLINDOLS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR | |
| DOP2005000208A (en) | PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR | |
| CL2012000885A1 (en) | Phenyloxadiazole derived compounds, prostaglandin synthase inhibitors (pgds); process for preparing said compounds; intermediate compounds; pharmaceutical composition comprising said compounds, useful for treating an inflammatory or allergic disorder. |